Discovery of Biaryl Amides as Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors

Yonghui Wang(Weifang People's Hospital), Xichen Lin(GlaxoSmithKline (China)), Yafei Huang(University of Denver), Yan Xu(Shanghai First People's Hospital), Qianqian Wu(GlaxoSmithKline (China)), Yaobang Cheng(GlaxoSmithKline (China)), Qinghua Meng(GlaxoSmithKline (China)), Ziqiang Cheng(Shandong Agricultural University), Qian Liu(Wuhan University), Wei Cai(GlaxoSmithKline (China)), Ling Zhou(China Pharmaceutical University), Fangbin Han(GlaxoSmithKline (China)), Feng Ren(Henan Medical University), Guifeng Zhang(GlaxoSmithKline (China)), John D. Elliott(GlaxoSmithKline (China)), Stewart Leung(GlaxoSmithKline (China)), Zhijun Xiang(GlaxoSmithKline (China)), Sijie Lu(GlaxoSmithKline (China)), Jia‐Ning Xiang(GlaxoSmithKline (China)), Ting Yang(GlaxoSmithKline (China)), Yonggang Zhao(GlaxoSmithKline (China))
ACS Medicinal Chemistry Letters
May 26, 2015
Cited by 76


Related Papers